BCAX (STOCKS)
Bicara Therapeutics Inc. Common Stock
$14.670000
-0.300000 (-2.00%)
Prev close: $14.970000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Claire Mazumdar
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $803.65M
- Employees
- 55
- P/E (TTM)
- -6.71
- P/B (TTM)
- 2.03
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
10
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.67 | $-0.56 | -0.1098 | -19.60% |
|
Jun 2025 (Q2)
|
$-0.50 | $-0.58 | +0.0799 | +13.78% |
|
Mar 2025 (Q1)
|
$-0.68 | $-0.42 | -0.2568 | -60.68% |
|
Dec 2024 (Q4)
|
$-0.39 | $-0.33 | -0.0601 | -18.22% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $19.95M |
| Operating Expenses | $141.12M |
| Research and Development | $112.00M |
| Other Operating Expenses | $29.12M |
| Operating Income/Loss | -$141.12M |
| Income/Loss From Continuing Operations After Tax | -$121.51M |
| Income/Loss From Continuing Operations Before Tax | -$121.17M |
| Income Tax Expense/Benefit | $343.00K |
| Net Income/Loss | -$121.52M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$121.52M |
| Net Income/Loss Available To Common Stockholders, Basic | -$121.52M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $5.37 |
| Diluted Earnings Per Share | $5.37 |
| Basic Average Shares | 16,910,410,373 |
| Diluted Average Shares | 16,910,410,373 |
| Assets | $424.69M |
| Current Assets | $297.37M |
| Noncurrent Assets | $127.32M |
| Fixed Assets | $135.00K |
| Other Non-current Assets | $127.18M |
| Liabilities | $21.91M |
| Current Liabilities | $21.03M |
| Wages | $3.99M |
| Other Current Liabilities | $17.04M |
| Noncurrent Liabilities | $880.00K |
| Equity | $402.78M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $402.78M |
| Liabilities And Equity | $424.69M |
| Net Cash Flow From Operating Activities | -$112.98M |
| Net Cash Flow From Operating Activities, Continuing | -$112.98M |
| Net Cash Flow From Investing Activities | -$236.16M |
| Net Cash Flow From Investing Activities, Continuing | -$236.16M |
| Net Cash Flow From Financing Activities | $56.00K |
| Net Cash Flow From Financing Activities, Continuing | $56.00K |
| Net Cash Flow | -$349.09M |
| Net Cash Flow, Continuing | -$349.09M |
| Comprehensive Income/Loss | -$121.66M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$121.66M |
| Other Comprehensive Income/Loss | $10.57M |